Results 91 to 100 of about 147,037 (114)

Corrigendum to “Trypanosoma spp. Neobats: Insights about those poorly known trypanosomatids” [Int. J. Parasitol. Parasites Wildl. 16 (2021) 145–152]

International Journal for Parasitology: Parasites and Wildlife
Fernanda Moreira Alves, Diana Azeredo Rangel, Emmanuel Messias Vilar, Márcio Galvão Pavan, Ricardo Moratelli, André Luiz Rodrigues Roque, Ana Maria Jansen   +6 more
doaj   +1 more source

Synopsis of adventive species of Coleoptera (Insecta) recorded from Canada. Part 5: Chrysomeloidea (Cerambycidae, Chrysomelidae, and Megalopodidae) [PDF]

, 2020
H.E.James Hammond, Lech Borowiec, E. Richard Hoebeke, Hume B. Douglas, Anthony Davies, Karine Savard, Caroline Bourdon, Jan Klimaszewski, David W. Langor   +8 more
core   +1 more source

Climatic Risk and Distribution Atlas of European Bumblebees

, 2015
Bumble bees represent one of the most important groups of pollinators. In addition to their ecological and economic relevance, they are also a highly charismatic group which can help to increase the interest of people in realizing, enjoying and ...
Oliver Schweiger, Pierre Rasmont
core  

USACE LNO trip slides Vietnam 19.201

Bridge 16 bypass on the same section of QL1 [QL1 between the MR 2/3 border and AP Long Lam].35mm color ...

core  

Some of the next articles are maybe not open access.

Related searches:

A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta® in healthy male subjects

Frontiers in Pharmacology, 2022
Guoping Yang, Can Guo, Yuxia Xiang
exaly  

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update

Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2022
Xueyan Zhang, Yuqing Lou, Tianqing Chu   +2 more
exaly  

Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial

Ophthalmology and Therapy, 2023
Mengli Zhu, Luosheng Tang, Jilong Hao
exaly  

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

Journal of Hematology and Oncology, 2023
Shenhong Qu, Yuxiang Ma, Hongyun Zhao
exaly  

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors

Frontiers in Immunology, 2023
Yun Fan
exaly  

A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk

Acta Pharmacologica Sinica, 2022
Zhenlin Zhang
exaly